3SBio Files For Approval For Interleukin-2 NuLeusin
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - 3SBio filed an application for the approval of NuLeusin with China's State FDA Nov. 10, hoping to make it the first product of its kind on the Chinese market, the Shenyang-based company announced
You may also be interested in...
Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
China's State FDA is expected to focus on new drug approvals this year in an attempt to get through its backlog of approval registrations.
Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
China's State FDA is expected to focus on new drug approvals this year in an attempt to get through its backlog of approval registrations.
Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
SHANGHAI - China's slow drug approvals, which can take as long as two years, are expected to speed up considerably in the Chinese Year of the Rabbit. China's State FDA is expected to focus on new drug approvals this year in an attempt to get through its backlog of approval registrations